[Skip to content]

Royal Brompton & Harefield NHS Foundation Trust
Our research
Search our Site
Bronchiectasis treatments

Our research

Active research studies

The Trust hosts a variety of research studies covering the breadth of its clinical practice. These are funded by a variety of sponsors including National Institute for Health Research (NIHR), UK research councils, European funding agencies, research charities and industry. 


Below is a list of approved projects that are currently recruiting volunteers.

  

Research studies

Specialty CategoryResearch titleStudy contact informationMore info
Interstitial lung disease & pulmonary fibrosisRituximab versus cyclophosphamide in connective tissue disease-ILD (RECITAL)Natalie WattMore info
Interstitial lung disease & pulmonary fibrosisA Phase 2 Trial to Evaluate the Efficacy of PRM-151 in Subjects with Idiopathic Pulmonary Fibrosis (IPF)Johanna LewisMore info
Interstitial lung disease & pulmonary fibrosisResponsiveness and MID of 4MGS in IPFClaire NolanMore info
Interstitial lung disease & pulmonary fibrosisThe predictive ability of 4MGS in IPFClaire NolanMore info
Interstitial lung disease & pulmonary fibrosisDiagnosis of CLAD using EITAnna ReedMore info
Interstitial lung disease & pulmonary fibrosisRandomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter, Exploratory Phase IIa Study to Assess Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of GLPG1690 Administered for 12 Weeks in Subjects with Idiopathic PulmonaSindhu SivagnanasithyarMore info
Interstitial lung disease & pulmonary fibrosisAmbulatory oxygen and health status in patients with lung fibrosisDr. Dina ViscaMore info
Interstitial lung disease & pulmonary fibrosisAn open-label multicenter phase II/III clinical study of inhaled Molgramostim in autoimmune pulmonary alveolar proteinosis patientsKatherine HubandMore info
Interstitial lung disease & pulmonary fibrosisPulmonary fibrosis in Interstitial Lung Diseases v2.1Professor Athol Wells or Gisela LindahlMore info
Interstitial lung disease & pulmonary fibrosisA phase IIa, openlabel study of multiple doses of GLPG1837 in subjects with cystic fibrosis and the G551D mutationSandra ScottMore info

See details of the Trust’s performance for all clinical trials reported to the NIHR (PDF, 276KB), for the set-up and delivery of studies in the period 1 October 2016 to 30 September 2017.

Royal Brompton

Sydney Street,
London SW3 6NP
Tel: +44 (0)20 7352 8121

Harefield